Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry

被引:50
作者
Dorlo, Thomas P. C. [1 ,2 ]
Hillebrand, Michel J. X. [1 ]
Rosing, Hilde [1 ]
Eggelte, Teunis A. [2 ]
de Vries, Peter J. [2 ]
Beijnen, Jos H. [1 ]
机构
[1] Netherlands Canc Inst, Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Acad Med Ctr, Dept Infect Dis & Trop Med AIDS, NL-1151 AZ Amsterdam, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2008年 / 865卷 / 1-2期
关键词
miltefosine; hexadecylphosphocholine; leishmaniasis; cutaneous leishmaniasis; liquid chromatography-tandem mass spectrometry; pharmacokinetics;
D O I
10.1016/j.jchromb.2008.02.005
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay for the quantification of miltefosine is presented. A 250 mu L human EDTA plasma aliquot was spiked with miltefosine and extracted by a solid-phase extraction method. Separation was performed on a Gemini C 18 column (150 mm x 2.0 mm I.D., 5 mu m) using an alkaline eluent. Detection was performed by positive ion electrospray ionization followed by triple-quadrupole mass spectrometry. The assay has been validated for miltefosine from 4 to 2000 ng/mL using 250 mu L human EDTA plasma samples. Results from the validation demonstrate that miltefosine can be accurately and precisely quantified in human plasma. At the lowest level, the intra-assay precision was lower than 10.7%, the inter-assay precision was 10.6% and accuracies were between 95.1 and 109%. This assay is successfully used in a clinical pharmacokinetic study with miltefosine. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 18 条
[1]
[Anonymous], 2013, Guidance for Industry: Bioanalytical Method Validation
[2]
Brouwers JFHM, 1998, J LIPID RES, V39, P344
[3]
Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives [J].
Croft, Simon L. ;
Engel, Juergen .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2006, 100 :S4-S8
[4]
Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs [J].
Croft, SL ;
Coombs, GH .
TRENDS IN PARASITOLOGY, 2003, 19 (11) :502-508
[5]
Drug resistance in leishmaniasis [J].
Croft, SL ;
Sundar, S ;
Fairlamb, AH .
CLINICAL MICROBIOLOGY REVIEWS, 2006, 19 (01) :111-+
[6]
Leishmaniasis [J].
Herwaldt, BL .
LANCET, 1999, 354 (9185) :1191-1199
[7]
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis [J].
Jha, TK ;
Sundar, S ;
Thakur, CP ;
Bachmann, P ;
Karbwang, J ;
Fischer, C ;
Voss, A ;
Berman, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (24) :1795-1800
[8]
LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY OF PHOSPHOLIPIDS USING ELECTROSPRAY-IONIZATION [J].
KIM, HY ;
WANG, TCL ;
MA, YC .
ANALYTICAL CHEMISTRY, 1994, 66 (22) :3977-3982
[9]
Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography [J].
Knebel, NG ;
Grieb, S ;
Winkler, M ;
Locher, M ;
van der Vlis, E ;
Verheij, ER .
JOURNAL OF CHROMATOGRAPHY B, 1999, 721 (02) :257-269
[10]
Lemke A, 2006, PHARMAZIE, V61, P406